dosage regimen, which can then be applied to design further Phase IIb and Phase III studies. Recent Publications 1. Wilkinson, Tom M (2012) Preexisting influenza-specific CD4+ T cells correlate
control of Serum Phosphorus (sP) in patients with chronic kidney disease undergoing dialysis. This study aimed to investigate the efficacy and safety of SFOH vs sevelamer carbonate in controlling ... hyperphosphataemia…
Biosimilar studies need to be conducted according to ICH-GCP and international regulations independent of the markets where Biosimilars will be registered. Especially small to midsize companies (sponsors ... partner…
powder. Study 2 was a randomised, open-label, replicate, six-way crossover, single-dose study in healthy subjects (n=30) to determine the bioequivalence of FF inhalation powder (single-strip ... analysis was also…
from the New Zealand MenB outbreak strain, fHbp, NadA and NHBA. In early clinical studies protective antibody levels with acceptable tolerability outcomes were observed in persons who received 4CMenB starting…
percentage of patients who had mucositis greater or equal to 2 in this study was 30.6% for the benzydamine group and 29.6% for propolis gel. For these patients the propolis ... showed better results than benzydamine…
talirane (Seattle Genetics) and Depatuxizumab mafodotin (AbbVie) are undergoing regulatory review or completing Phase III clinical studies. In all, more than 60 ADCs are in clinical trails with over
poor PF. Till date, there are no clinical practice guidelines or randomized prospective phase III studies to treat this subset of high-risk patients with RT dose escalation using advanced ... advanced RT techniques for…
well as tyrosine kinase inhibitors that disable the activating portion of the receptor. Preclinical studies in pancreatic cancer models have demonstrated the efficacy of both of these treatment options ... first…
dose, to select right patients and to supply right medication. Pharmacodynamics (PD) is the study of the biochemical and physiological effects of drugs on the body by interacting drugs with ... drug candidates and…
monoclonal antibody directed against PDGFR alpha. The results of a randomized phase 2 study comparing olaratumab plus doxorubicin with doxorubicin alone, showed a statistically significant improvement in progression…
everolimus, an mTOR inhibitor, which was approved on the basis of a landmark phase III study (RADIANT-3). At the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, several ... advanced NET. Three…
degradation. Thus development of more metabolically stable analogues is of intense interest .Structure activity studies of SRIF-14 have shown that Trp8 and Lys9 comprise the critical β-turn ... especially significant in…
controlled, parallel design, single-dose blinded and single center clinical trial in Japan. This study will enroll 60 patients diagnosed with PAD with intermittent claudication. Subjects who meet eligibility criteria…
prognosis. New agents are desperately needed, yet nearly every Phase III study of GBM patients conducted in the last 25 years has failed to show a significant improvement in outcomes
differently in terms of regulatory approvals in most countries, that is indication-specific phase III studies are generally not required in order to gain approval. As a result, less
stay alive – hence the C5 and LTB4 inhibition. This treatment is in phase III studies for two rare but catastrophic illnesses, Bullous Pemphigoid and Thrombotic microangiopathy (TMA). As severe COVID
pegylated forms of interferon. The interim 20-week results of BCD-054 III phase study showed significant reduction in brain MRI disease activity on PEG interferon β1a therapy compared with
trial data that have been neutral or even potentially harmful when assessed in phase III studies. Lewy body dementia is a common but frequently under diagnosed cause of dementia often
approximating 30 months were noted with historic controls less than 5 months. A Phase III study is being planned with the addition of low dose chemotherapy added to minimize
such must be treated accordingly. Therefore, phase I, PK/PD, and phase III studies must be conducted to demonstrate similarity and equivalency in order that the regulatory authorities will sign
inhibitor drug of the JAK family of protein kinases. The results from two Phase III studies in myelofibrosis (COMFORT-I, COMFORT-II) demonstrate the effectiveness of Ruxolitinib in patients with
review. All randomized-controlled trials have shown significant improvements in urinary symptoms. Recent Phase III studies have also shown improvements in patient satisfaction and quality of life. Significant…
treatment for relapsing–remitting multiple sclerosis after positive results from two large pivotal Phase III studies. Approval is also imminent in the EU, where BG-12 has received a positive
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.